Reponex: Interview with CMO Christopher Burton
Reponex: Interview with CMO Christopher Burton
We had the pleasure of interviewing CMO Christopher Burton from Reponex Wednesday the 11th. of October 2023. Reponex is a wholly owned subsidairy of Pharma Equity Group.
Reponex focus is on repositioning and reformulation of existing drugs. In big pharma repositioning is known as life cycle management. Reponex strategy doesn't violate existing patents on the drug they reposition or reformulate. Reponex got 5 projects in the pipeline and solely focus on phase 2 projects. The commercial strategy is to either find a partner for the phase 3 or to out license the project. There is a great deal of synergies between the 5 projects.
Listen to the interview here: CMO Christopher Burton
Disclaimer: HC Andersen Capital receives payment from Pharma Equity Group for a Digital IR/Corporate Visibility subscription agreement. /Claus Thestrup 8:30 AM 16-10-2023.
Pharma Equity Group develops new medicines for the local treatment of serious and life-threatening inflammatory diseases for which there is currently no adequate treatment. The company uses repositioning of existing drugs and brings drug candidates to a clinical phase III stage, after which it is handed over to a strategic partner who will complete the development of the products and bring them to market, either independently or in collaboration with the company.
Read more on company page